Posted by Michael Wonder on 25 Nov 2022
Hugel's 'Letybo' first in Korea to obtain marketing approval from Australia
24 November 2022 - Obtained marketing approval on the 23rd (local time) from the TGA of Australia for the indication of glabellar lines.
Hugel announced today that they obtained marketing approval for 50 and 100 units of its botulinum toxin called 'Letybo' for the indication of glabellar lines from the TGA of Australia on the 23rd (local time).
Hugel plans to complete the first shipment and launch in the local market within the first quarter of 2023. The local subsidiary will be in charge of distribution and marketing.
